BBIO FY2025 SEC EDGAR DEF 14A #92 of 168 in industry

BridgeBio Pharma, Inc. CEO pay ratio

The CEO earned $14.9M in FY2025 against median worker pay of $399,120 · Chemicals & Pharmaceuticals.

Chemicals & Pharmaceuticals peers All rankings
State
DE
Filing date
2026-04-24
Industry
Chemicals & Pharmaceuticals
Industry rank
#92/168

Data updated August 2026

Subscribe to BridgeBio Pharma, Inc. CEO pay filing updates (RSS)

CEO-to-worker pay ratio
37:1
Below Average (Scale: 0–1000:1)
CEO pay
$14.9M
Median worker
$399,120

Answer first

BridgeBio Pharma, Inc.'s FY2025 CEO total of $14.9M ranks #312 of 1,423 complete filings; its 37:1 pay ratio ranks #1084. Dollar rank is not ratio rank.

According to the same FY2025 complete-filing cohort used on the rankings boards (CEO total, median worker, and ratio all present). Median worker pay is $399,120. Industry placement uses the FY2025 SIC-28 peer cohort (# 92 of 168, 46th percentile - below the industry median pay ratio). Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.

Dollar rank
#312
$14.9M of 1,423 FY2025
Ratio rank
#1084
37:1 of 1,423
Industry pct
46th
below the industry median pay ratio

How BridgeBio Pharma, Inc. ranks nationally

BridgeBio Pharma, Inc. CEO pay vs. every FY2025 complete filing

Total CEO compensation, the full national distribution, this company marked

$14,944,585 Top 22% higher than 78% of 1,423 companies

$0–$2,500,000: 304 companies (21%). Below this entry. $2,500,000–$5,000,000: 182 companies (13%). Below this entry. $5,000,000–$7,500,000: 208 companies (15%). Below this entry. $7,500,000–$10,000,000: 192 companies (13%). Below this entry. $10,000,000–$12,500,000: 139 companies (10%). Below this entry. $12,500,000–$15,000,000: 91 companies (6%). This entry sits in this band. $15,000,000–$17,500,000: 88 companies (6%). Above this entry. $17,500,000–$20,000,000: 54 companies (4%). Above this entry. $20,000,000–$22,500,000: 24 companies (2%). Above this entry. $22,500,000–$25,000,000: 34 companies (2%). Above this entry. $25,000,000–$27,500,000: 24 companies (2%). Above this entry. $27,500,000–$30,000,000: 16 companies (1%). Above this entry. $30,000,000–$32,500,000: 10 companies (1%). Above this entry. $32,500,000–$35,000,000: 7 companies (0%). Above this entry. $35,000,000–$37,500,000: 9 companies (1%). Above this entry. $37,500,000–$40,000,000: 6 companies (0%). Above this entry. $40,000,000–$42,500,000: 1 companies (0%). Above this entry. $42,500,000–$45,000,000: 1 companies (0%). Above this entry. $45,000,000–$47,500,000: 6 companies (0%). Above this entry. $47,500,000–$50,000,000: 27 companies (2%). Above this entry. This company $0 $50M+ every complete-filing company, bucketed by value

Each bar is a $2500K-wide band; taller bars hold more companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source SEC DEF 14A Section 953(b) disclosures, PlainCEOPay extract · FY2025

BridgeBio Pharma, Inc. vs. Chemicals & Pharmaceuticals peers

CEO total pay ($14.9M) against pay ratio (37:1) for BridgeBio Pharma, Inc. (marked) and its 5 closest same-industry peers, against the Chemicals & Pharmaceuticals industry median on both axes.

Pay + gap both highContained pay, wide gapHigh pay, contained gapBelow peer norms on both1634542.85801442.9996834314135243.118302143.234.6:136.6:138.5:140.4:142.4:1CEO total payPay ratio (CEO : median worker)BridgeBio Pharma, Inc., CEO total pay: 14944585 · Pay ratio (CEO : median worker): 37:1BridgeBio Pharma, Inc.Cryoport, Inc., CEO total pay: 2392161 · Pay ratio (CEO : median worker): 37:1Cryoport, Inc.Xenon Pharmaceuticals Inc., CEO total pay: 9118206 · Pay ratio (CEO : median worker): 37:1Xenon Pharmaceuticals Inc.Ultragenyx Pharmaceutical Inc., CEO total pay: 11490288 · Pay ratio (CEO : median worker): 38:1Ultragenyx Pharmaceutical Inc.Rhythm Pharmaceuticals, Inc., CEO total pay: 17544525 · Pay ratio (CEO : median worker): 36:1Rhythm Pharmaceuticals, Inc.Evolus, Inc., CEO total pay: 6412214 · Pay ratio (CEO : median worker): 35:1Evolus, Inc.
BridgeBio Pharma, Inc. vs. Chemicals & Pharmaceuticals peers, plotted against the industry's $7.9M median CEO total and 42:1 median pay ratio.

Ratio bands among Chemicals & Pharmaceuticals peers

Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.

CEO Compensation Breakdown, FY2025

A component-level pay breakdown is not reported in BridgeBio Pharma, Inc.'s structured SEC pay-ratio disclosure. See our methodology →

Filing-year trail · BridgeBio Pharma, Inc.

Complete DEF 14A pay-ratio filings for this CIK across FY2021–2025. Year-over-year deltas compare adjacent filing years only; incomplete dollar rows are omitted (same completeness gate as the hero figures).

Latest ratio
37:1
FY2025
vs prior FY
-8:1
from FY2024 45:1
CEO $ YoY
-4.1%
$14.9M latest
Filings shown
5
FY2021–2025
BridgeBio Pharma, Inc. CEO total compensation, median worker pay, and pay ratio by fiscal year from SEC EDGAR DEF 14A.
FY CEO pay Δ pay Median worker Pay ratio Δ ratio
2021 $25.4M - $508,054 50:1 -
2022 $6.7M -74% $273,664 24:1 -26:1
2023 $12.2M +82% $392,040 31:1 +7:1
2024 $15.6M +28% $348,914 45:1 +14:1
2025 $14.9M -4.1% $399,120 37:1 -8:1

Source: SEC EDGAR DEF 14A pay-ratio disclosures for CIK 1743881, FY2021–2025. Adjacent-year deltas only.

Industry Comparison - Chemicals & Pharmaceuticals

This Company's Ratio
37:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$14.9M
Companies in Industry
168
vs. Industry Median
Below
#92 of 168 by pay ratio in this industry View all companies in Chemicals & Pharmaceuticals →

BridgeBio Pharma, Inc.: MODEST · HEAVY pay ratio

BridgeBio Pharma, Inc.'s FY2025 CEO total $14.9M ranks #312 of 1,423 complete filings (higher third by dollars). the CEO earned 37× the median employee ($399,120) in FY2025.

Median employee $399,120 (ELITE-MED); MODEST · HEAVY stamps put about 37 median-wage years per CEO year.

CEO Total Pay

$14.9M

FY2025 Summary Compensation, above median

Pay Ratio

37:1

Below typical

BridgeBio Pharma, Inc. in the higher-dollar third

BridgeBio Pharma, Inc.'s FY2025 CEO total $14.9M ranks #312 of 1,423 complete filings (higher third by dollars). The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; BridgeBio Pharma, Inc.'s $14.9M CEO total is above the $7.9M industry median CEO pay.

Dollar rank #312 and ratio rank #1084 split - treat 37:1 as a disclosure, not a fairness score. Open Chemicals & Pharmaceuticals peers.

Key Data, FY2025

Total Compensation
$14.9M
Median Employee Pay
$399,120
Pay Ratio
37:1
Filing Date
2026-04-24

Company Info

Ticker
BBIO
CIK
1743881
Industry
Chemicals & Pharmaceuticals
SIC Code
2834
State
DE
View SEC filings →
SEC EDGAR DEF 14A for CIK 1743881, FY2025. Informational only, not investment advice. Verify on EDGAR.

Read our methodology - how this data is sourced, computed, and verified. BridgeBio Pharma, Inc.'s FY2025 CEO total $14.9M ranks #312 of 1,423 complete filings (higher third by dollars).

Read with BridgeBio Pharma, Inc.

ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps MODEST · HEAVY · ELITE-MED.

Astrana Health, Inc. · HEAVY

ABS(ceo_total_comp) peer at $15.0M (Δ $10K heavier vs BridgeBio Pharma, Inc.); STEEP · PAR-MED vs this page's MODEST · HEAVY · ELITE-MED.
Diamondback Energy, Inc. · HEAVY

ABS(ceo_total_comp) peer at $14.9M (Δ $13K lighter vs BridgeBio Pharma, Inc.); MID · ELITE-MED vs this page's MODEST · HEAVY · ELITE-MED.
Nicolet Bankshares Inc · HEAVY

ABS(ceo_total_comp) peer at $15.0M (Δ $19K heavier vs BridgeBio Pharma, Inc.); STEEP · PAR-MED vs this page's MODEST · HEAVY · ELITE-MED.
Elanco Animal Health Inc · HEAVY

ABS(ceo_total_comp) peer at $15.0M (Δ $20K heavier vs BridgeBio Pharma, Inc.); STEEP · HIGH-MED vs this page's MODEST · HEAVY · ELITE-MED.
Cryoport, Inc. (SIC 28 pole)

Cryoport, Inc. stamps MODEST · MID$ nearest in-SIC by ABS(pay_ratio) to BridgeBio Pharma, Inc.'s MODEST filing.
National dual ranks · #312/#1084

BridgeBio Pharma, Inc.'s FY2025 package sits #312 by CEO dollars and #1084 by ratio under HEAVY · MODEST.
Ratio primer · MODEST

BridgeBio Pharma, Inc.'s MODEST stamp sits in the lower Item 402(u) band - start with how the ratio is disclosed before comparing peers.
Data sourced from SEC EDGAR DEF 14A for BridgeBio Pharma, Inc. (CIK 1743881), FY2025. See our methodology. Aggregated by PlainCEOPay as of August 2026.

Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.